KIORA PHARMACEUTICALS, INC. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic
KIORA PHARMACEUTICALS, INC. (KPRX) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of $3.59 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2025-03-25
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2024-12-31 was -$4.22M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2024-09-30 was -$3.41M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-12-31 was -$2.27M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-09-30 was -$6.29M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2024 was $3.59M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2023 was -$13.04M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2022 was -$13.58M.
| Period end | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 6 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$7.64M derived: sum of 2 quarters · filed 2025-03-25 | $3.59M 10-K · filed 2025-03-25 | |
| 2024-09-30 | -$3.41M 10-Q · filed 2024-11-08 | $7.82M 10-Q · filed 2024-11-08 | ||
| 2023-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$8.56M derived: sum of 2 quarters · filed 2025-03-25 | -$13.04M 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$6.29M 10-Q · filed 2024-11-08 | -$10.78M 10-Q · filed 2024-11-08 | ||
| 2022-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$7.62M derived: sum of 2 quarters · filed 2024-03-25 | -$13.58M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$5.12M 10-Q · filed 2023-11-09 | -$11.09M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |